Inventor · disambiguated record
Fernando Donate
Also filed as: DONATE FERNANDO
6 granted patents·24 pending applications·23 citations·filing 2002–2025
73Inventor score
Top patents by PatentIndex Score
30 records- 0181US11278532B2Estrogen receptor modulators for treating mutantsRECURIUM IP HOLDINGS LLC·Filed 2020·Granted Mar 22, 2022·1 cites·22 claims
- 0281US7189865B2Thiomolybdate analogues and uses thereofUNIV MICHIGAN·Filed 2003·Granted Mar 13, 2007·22 cites·112 claims
- 0366US2024261295A1Combinations of wee1 inhibitors and anti-cd47 antibodiesRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 0464US2024299395A1Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitorsRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 0564US2024325397A1Use of combination therapy for treating cancerRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 0663US2024325412A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 0763US2024335447A1Wee1 inhibitor for cancerRECURIUM IP HOLDINGS LLC·Filed 2024·Application pending·0 cites
- 0861US7119069B2Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agentATTENUON LLC·Filed 2006·Granted Oct 10, 2006·0 cites·17 claims
- 0961US2024408097A1Wee1 inhibitors and methods for treating cancerRECURIUM IP HOLDINGS LLC·Filed 2023·Application pending·0 cites
- 1061US2022125769A1Estrogen receptor modulators for treating mutantsRECURIUM IP HOLDINGS LLC·Filed 2022·Application pending·0 cites
- 1158US7098187B2Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agentATTENUON LLC·Filed 2003·Granted Aug 29, 2006·0 cites·17 claims
- 1258US2024197743A1Wee1 compound for treating uterine serous carcinomaRECURIUM IP HOLDINGS LLC·Filed 2022·Application pending·0 cites
- 1356US2023381172A1Combinations of bcl-2 inhibitors with chemotherapeutic agentsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 1455US7517855B2Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereofATTENUON LLC·Filed 2003·Granted Apr 14, 2009·0 cites·9 claims
- 1554US11292837B2Nectin-4 binding proteins and methods of use thereofAGENSYS INC·Filed 2018·Granted Apr 5, 2022·0 cites·17 claims
- 1654US2023210854A1Mono- and combination therapiesRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 1754US2023158048A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 1853US2023065577A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 1952US2023054854A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2052US2023068370A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2151US2023054767A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2251US2023008362A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2350US2023042653A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2450US2023053946A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2549US2023087941A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
- 2646US2025262214A1Intermittent dosing regimen for azenosertib in treating cancerZENO MAN INC·Filed 2025·Application pending·0 cites
- 2746US2025205240A1CombinationsRECURIUM IP HOLDINGS LLC·Filed 2025·Application pending·0 cites
- 2843US2009170123A1Identification of Novel Protein Targets on the Surface of Stressed CellsDONATE FERNANDO·Filed 2006·Application pending·0 cites
- 2938US2005124794A1Cell surface tropomyosin as a target of angiogenesis inhibitionFiled 2003·Application pending·0 cites
- 3036US2003082740A1Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agentFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fernando Donate files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →